If you want the broader context, start with the BPC-157 hub page, then use the deep dives for mechanism, evidence, safety and status, and quality and COA
The REDEFINE clinical trial program has established that: Cagrilintide 2.4 mg + Semaglutide 2.4 mg weekly produces superior weight loss compared to either agent alone The combination achieved 22.7% mean weight reduction at 68 weeks Side effect profiles were manageable with proper dose escalation The amylin + GLP-1 agonist combination demonstrated synergistic effects This validated combination demonstrates that pairing cagrilintide with incretin-based therapies can work effectively
Yes, the physical storage rules are identical: 2 to 8 C refrigeration, no freezing, no temperatures above 25 C, 14 to 21 days reconstituted with bacteriostatic water
Advantage: Potential for higher bioavailability than standard oral ingestion Challenge: Peptides are poorly absorbed through intact mucosal membranes without transport mechanisms Evidence: No studies confirm enhanced sublingual bioavailability for Dihexa Standard oral (swallowed): Tablets swallowed with water, absorbed through the gastrointestinal tract
